Additive solution-7 reduces the red blood cell cold storage lesion

Background Transfusion of long‐stored red blood cells (RBCs) is associated with decreased in vivo RBC recovery, delivery of RBC breakdown products, and increased morbidity and mortality. Reducing the burden of this RBC “storage lesion” is a major challenge in transfusion medicine. Additive solution‐...

Full description

Saved in:

Bibliographic Details
Published in:	Transfusion (Philadelphia, Pa.) Vol. 55; no. 3; pp. 491 - 498
Main Authors:	Cancelas, Jose A., Dumont, Larry J., Maes, Lou A., Rugg, Neeta, Herschel, Louise, Whitley, Pamela H., Szczepiokowski, Zbigniew M., Siegel, Alan H., Hess, John R., Zia, Majid
Format:	Journal Article
Language:	English
Published:	United States Blackwell Publishing Ltd 01.03.2015 Wiley Subscription Services, Inc
Subjects:	Adenine - pharmacology Anticoagulants - pharmacology Blood Preservation - methods Buffers Cell Survival - drug effects Chromium Radioisotopes - blood Citrates - pharmacology Cold Temperature - adverse effects Cryoprotective Agents - pharmacology Erythrocytes - cytology Erythrocytes - drug effects Erythrocytes - metabolism Glucose - pharmacology Hemolysis - drug effects Humans Hydrogen-Ion Concentration In Vitro Techniques Leukocyte Reduction Procedures - instrumentation Mannitol - pharmacology Pharmaceutical Solutions - pharmacology Prospective Studies Sodium Chloride - pharmacology Time Factors
ISSN:	0041-1132, 1537-2995, 1537-2995
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Background Transfusion of long‐stored red blood cells (RBCs) is associated with decreased in vivo RBC recovery, delivery of RBC breakdown products, and increased morbidity and mortality. Reducing the burden of this RBC “storage lesion” is a major challenge in transfusion medicine. Additive solution‐7 (AS‐7) is a new RBC storage solution designed to improve RBC metabolism by providing phosphate and increasing buffering capacity. Study Design and Methods Storage quality in AS‐7 was measured in a prospective, randomized, three‐center trial using units of whole blood from healthy human subjects whose RBCs were stored for up to 56 days in AS‐7 (n = 120) or for 42 days in the control solution AS‐1 (n = 60). Results Hemolysis and shedding of protein‐containing microvesicles were significantly reduced in RBCs stored in AS‐7 for 42 and 56 days compared with RBCs stored in AS‐1. Autologous in vivo recoveries of RBCs stored in AS‐7 was 88 ± 5% at 42 days (n = 27) and 82 ± 3% at 56 days (n = 27), exceeding recoveries of RBCs stored in currently used solutions. Conclusion Increasing the phosphate, pH range, and buffer capacity of a RBC storage system allowed RBCs to be stored better and longer than currently approved storage systems. AS‐7 ameliorates the long‐term storage lesion resulting in significantly increased viability in vitro and in vivo.
Bibliography:	ArticleID:TRF12867 U.S. Army Medical Research and Materiel Command - No. W81XWH0610766 ark:/67375/WNG-PM8DXP1P-J istex:46B0A65442DF2E75304360BE17FD18B9ACB93066 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3
ISSN:	0041-1132 1537-2995 1537-2995
DOI:	10.1111/trf.12867